ReviewLancet (London, England)2019
Advances in β-cell replacement therapy for the treatment of type 1 diabetes.
Review in Lancet (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 1 synthesis or guideline pooled it, 194 citations in OpenAlex.
- First world consensus conference on pancreas transplantation: Part I-Methods and results of literature search.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2021Pooled it
- Encapsulated stem cell-derived β cells exert glucose control in patients with type 1 diabetes.Nature biotechnology · 2024Trial
- Stiffness-tunable oral nanoparticles facilitate damaged islet β cell restoration for diabetes treatment.Science advances · 2026Article
- Organoid Technology as a Promising Frontier in Organ Transplantation and Regenerative Medicine.International journal of stem cells · 2026Review
- Optimizing Post-Transplantation Detection of Subcutaneously Transplanted Islets Using Dithizone Staining.bioRxiv : the preprint server for biology · 2026Article
- Combination of proton-pump inhibitor and anti-CD3 F(ab')Immunotherapy advances · 2026Article
- Optimizing post-transplantation detection of subcutaneously transplanted islets using dithizone staining.BMC methods · 2026Article
- Impact of preformed donor-specific anti-HLA antibodies on pancreatic islet transplantation outcomes: do they matter as they do in solid organ transplantation?Frontiers in immunology · 2026Review
- From cold chain to ambient: Benefits, risks, and evidence across cell therapy logistics.Molecular therapy. Methods & clinical development · 2025Review
- Perceptions of the Benefits and Risks of Novel Therapies for Type 1 Diabetes: A Qualitative Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Review
- March5-mediated Trim28 degradation preserves islet β-cell function in mice.Nature communications · 2025Article
- Rat Islet pECM Hydrogel-Based Microencapsulation: A Protective Niche for Xenotransplantation.Gels (Basel, Switzerland) · 2025Article
- Stem cell therapies for diabetes.Nature medicine · 2025Review
- Methylprednisolone Protects Human Pancreatic Beta Cells From Inflammation-induced Damage.Transplantation direct · 2025Article
- Pancreatic Ductal Cell Heterogeneity: Insights into the Potential for β-Cell Regeneration in Diabetes.Stem cell reviews and reports · 2025Review
- Oxygen dynamics and delivery strategies to enhance beta cell replacement therapy.American journal of physiology. Cell physiology · 2025Review
- Article
- EndoCompass Project: Research Roadmap for Calcium and Bone Endocrinology.Hormone research in paediatrics · 2025Review
- Harnessing cellular therapeutics for type 1 diabetes mellitus: progress, challenges, and the road ahead.Nature reviews. Endocrinology · 2025Review
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
Abstract
The main goal of treatment for type 1 diabetes is to control glycaemia with insulin therapy to reduce disease complications. For some patients, technological approaches to insulin delivery are inadequate, and allogeneic islet transplantation is a safe alternative for those patients who have had severe hypoglycaemia complicated by impaired hypoglycaemia awareness or glycaemic lability, or who already receive immunosuppressive drugs for a kidney transplant. Since 2000, intrahepatic islet transplantation has proven efficacious in alleviating the burden of labile diabetes and preventing complications related to diabetes, whether or not a previous kidney transplant is present. Age, body-mass index, renal status, and cardiopulmonary status affect the choice between pancreas or islet transplantation. Access to transplantation is limited by the number of deceased donors and the necessity of immunosuppression. Future approaches might include alternative sources of islets (eg, xenogeneic tissue or human stem cells), extrahepatic sites of implantation (eg, omental, subcutaneous, or intramuscular), and induction of immune tolerance or encapsulation of islets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.